The European market size for the biologics safety testing market is expected to grow at a CAGR of 13.25% from 2022 to 2027 and be worth USD 2 billion by 2027 from USD 1.07 billion in 2022.
Biological safety testing is one of the most important aspects since it is the foundation for decontaminating biological medications, laboratories, and healthcare facilities. As the European region battles pandemics, it's critical to ensure that drugs and medical equipment used to treat patients are contaminated-free. Microbial and viral contamination is inherently present in biological products generated from mammalian cell lines. As a result, more rigorous safety testing is being used to verify that biological materials are safe and free of contaminants throughout the development process.
The rising demand for rehabilitative treatments for life-threatening diseases such as cancer and diabetes is accelerating the need for drug R&D. As a result, for effective quality control and testing, there is a necessity for biologics safety testing kits. The aforementioned factor is expected to significantly increase the European biologics safety testing market during the forecast period.
Furthermore, as the use of single-use medical goods grows, pharmaceutical companies are focusing on developing safe products and establishing sterility assurance, which is anticipated to accelerate the market's growth rate. In addition, increased demand for medical products due to the rising prevalence of targeted diseases and easier access to healthcare services is another key factor expected to boost the market growth during the forecast period.
However, due to a lack of education and training, several variables are also experiencing a significant shortage of untapped human resources. The scarcity of qualified specialists may hinder the adoption of new technologies and procedures, hampering the biologics safety testing market's growth. On the other hand, the biological safety process is time-consuming and complex, which is projected to slow market growth.
This report on the European biologics safety testing market has been segmented and sub-segmented into the following categories.
By Products & Services:
By Test Type:
By Application:
By End-User:
By Country:
Geographically, Europe held the second-largest share in the global market in 2022 and is expected to grow significantly during the forecast period. The rapid growth of the pharmaceutical and medical industries is a significant factor affecting the regional development of the European biologics safety testing market. In addition, growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing consumer awareness about product safety, and the presence of significant market players in this region are all influencing the biologics safety testing market on a regional level.
The German government has invested in life science innovation projects to aid research institutes in finding cures for chronic diseases. In addition, the countries such as Germany and U.K, France have a significant revenue share in the European biological safety testing market.
KEY MARKET PLAYERS:
Charles River Laboratories International Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, SGS S.A., Thermo Fisher Scientific Inc., Pace Analytical Services Inc., WuXi AppTec, and Cytovance Biologics Inc. are some of the prominent companies operating in the European biologics safety testing market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region